SCHEMBL6886441

SCHEMBL6886441

COCOc1ccc(C)c(B(O)O)c1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.39
HPGD P15428 3/20 0.37
PTPN1 P18031 1/20 0.36
RAB9A P51151 2/20 0.35
FYN P06241 4/20 0.35
ENPP2 Q13822 2/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
FKBP1A P62942 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MAPT P10636 3/20 0.33
NPC1 O15118 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MCL1 Q07820 1/20 0.33
DDX3X O00571 1/20 0.32
FFAR1 O14842 1/20 0.32
GAA P10253 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29953230 0.86 HPGD (0.37) ATMHPGDPTPN1RAB9AFYN
SCHEMBL16335197 0.86 HPGD (0.37) ATMHPGDPTPN1RAB9AFYN
SCHEMBL6472212 0.83 NQO1 (0.38) ATMHPGDRAB9AFKBP1ASMN1; SMN2
SCHEMBL3592109 0.82 TUBB4A (0.41) PTPN1FYNENPP2CA1CA2
SCHEMBL23673443 0.81 FYN (0.34) FYNENPP2CA1CA2FFAR1
SCHEMBL29887229 0.81 FYN (0.34) FYNENPP2CA1CA2FFAR1
SCHEMBL10271335 0.79 HPGD (0.49) ATMHPGDRAB9AFKBP1ASMN1; SMN2
SCHEMBL1960037 0.79 ENPP2 (0.50) RAB9AENPP2CA1CA2SMN1; SMN2
SCHEMBL772019 0.79 ENPP2 (0.37) PTPN1FYNENPP2CA1CA2
SCHEMBL29937225 0.78 FYN (0.35) ATMFYNENPP2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304537-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME REPARE THERAPEUTICS INC. (CA) 2025-10-02 US disclosed
CN-119894872-A Heteroarenes, pharmaceutical compositions containing heteroarenes, and methods of use thereof 修复治疗公司 2025-04-25 CN disclosed
EP-4526293-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME Repare Therapeutics Inc. (CA) 2025-03-26 EP disclosed
WO-2023220831-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME REPARE THERAPEUTICS INC. (CA) 2023-11-23 WO disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-6831106-B1 Selective activity on cell proliferation and differentiation without displaying any hypercalcaemiant nature GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304537-A1 HETEROARENES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME CSNK1A1, CSNK1G1, CSNK2A1 ATM 261/4885HPGD 3321/4885PTPN1 561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.